Marcel M. Verbeek mainly investigates Alzheimer's disease, Pathology, Internal medicine, Cerebrospinal fluid and Dementia. His Alzheimer's disease research is multidisciplinary, incorporating elements of Amyloid beta, Pathogenesis and Degenerative disease. Pathology connects with themes related to Pericyte in his study.
His Internal medicine study combines topics in areas such as Gastroenterology, Endocrinology and Oncology. His research in Cerebrospinal fluid intersects with topics in Protein S, Neurofilament, GFAP stain, Immunology and Dementia with Lewy bodies. His study in Dementia is interdisciplinary in nature, drawing from both Neurology, Cognition and Geriatrics.
Marcel M. Verbeek mostly deals with Pathology, Cerebrospinal fluid, Internal medicine, Disease and Alzheimer's disease. His research in Dementia, Cerebral amyloid angiopathy, Senile plaques, Amyloid beta and Dementia with Lewy bodies are components of Pathology. His Amyloid beta research includes themes of Pericyte and Perlecan.
The concepts of his Cerebrospinal fluid study are interwoven with issues in Multiple sclerosis, Immunology, Differential diagnosis, Biomarker and Atrophy. His work is dedicated to discovering how Internal medicine, Endocrinology are connected with Homovanillic acid and other disciplines. His Alzheimer's disease research is multidisciplinary, relying on both Degenerative disease and Amyloid.
The scientist’s investigation covers issues in Internal medicine, Disease, Cerebrospinal fluid, Pathology and Biomarker. His Internal medicine study combines topics from a wide range of disciplines, such as Gastroenterology, Endocrinology and Oncology. His Disease research includes elements of Diagnostic accuracy, Neurology, Atrophy and Intensive care medicine.
His work carried out in the field of Cerebrospinal fluid brings together such families of science as Csf biomarkers, Central nervous system, Neuroinflammation, Neuroimaging and Biomarker discovery. His Cerebral amyloid angiopathy, Risk factor and Glial fibrillary acidic protein study, which is part of a larger body of work in Pathology, is frequently linked to Clinical Practice, bridging the gap between disciplines. Marcel M. Verbeek has included themes like Rotterdam Study, Amyloid β, Alzheimer's disease and Cognition in his Dementia study.
Disease, Internal medicine, Dementia, Biomarker and Cerebrospinal fluid are his primary areas of study. His Disease study incorporates themes from Gastroenterology, Neuroscience and Intensive care medicine. His work on Internal medicine is being expanded to include thematically relevant topics such as Endocrinology.
His biological study spans a wide range of topics, including White matter, Hyperintensity, Cognition, Alzheimer's disease and Neurology. His Biomarker research incorporates themes from Clinical neurochemistry, Multiple sclerosis, Clinical study design and Amyloid. Cerebrospinal fluid is a subfield of Pathology that Marcel M. Verbeek investigates.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.
Niklas Mattsson;Henrik Zetterberg;Oskar Hansson;Niels Andreasen.
Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study
Pieter Jelle Visser;Pieter Jelle Visser;Frans Verhey;Dirk L Knol;Philip Scheltens.
Lancet Neurology (2009)
Prediction of poor outcome within the first 3 days of postanoxic coma
E.G.J. Zandbergen;A. Hijdra;J. H.T.M. Koelman;A. A.M. Hart.
Glial and neuronal proteins in serum predict outcome after severe traumatic brain injury
P.E. Vos;K.J.B. Lamers;J.C.M. Hendriks;M. van Haaren.
The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers
Niklas Mattsson;Ulf Andreasson;Staffan Persson;Hiroyuki Arai.
Alzheimers & Dementia (2011)
Glucose transporter-1 deficiency syndrome: The expanding clinical and genetic spectrum of a treatable disorder
Wilhelmina G. Leen;Joerg Klepper;Marcel M. Verbeek;Maike Leferink.
Prognosis of coma after therapeutic hypothermia: a prospective cohort study.
Aline Bouwes;Jan M. Binnekade;Michael A. Kuiper;Frank H. Bosch.
Annals of Neurology (2012)
CSF biomarker variability in the Alzheimer's Association quality control program
Niklas Mattsson;Niklas Mattsson;Ulf Andreasson;Staffan Persson;Maria C. Carrillo.
Alzheimers & Dementia (2013)
Protein S-100B, neuron-specific enolase (NSE), myelin basic protein (MBP) and glial fibrillary acidic protein (GFAP) in cerebrospinal fluid (CSF) and blood of neurological patients.
K.J.B. Lamers;P.J.E. Vos;M.M. Verbeek;F. Rosmalen.
Brain Research Bulletin (2003)
Induction of alpha-smooth muscle actin expression in cultured human brain pericytes by transforming growth factor-beta 1.
M. M. Verbeek;I. Otte-Höller;P. Wesseling;D. J. Ruiter.
American Journal of Pathology (1994)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: